MedTrace Logo

ToleroMune Ragweed Follow up Study

NCT01448603 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2012-05-17

No results posted yet for this study

Summary

Ragweed is the primary cause of autumn allergies. The ragweed season begins in mid-August. In the third National Health and Nutrition Examination Surveys54.3% of the population had positive test responses to one or more allergens, with the prevalence for short ragweed being 26.2%

The purpose of this observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to ragweed allergen in the EEC among subjects who completed all dosing visits and the post treatment challenge (PTC) visit in study TR002 approximately one year after the start of treatment.

Conditions

  • Ragweed Allergy
  • Rhinoconjunctivitis

Interventions

BIOLOGICAL

Placebo

No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.

BIOLOGICAL

ToleroMune Ragweed

No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.

Sponsors & Collaborators

  • Adiga Life Sciences, Inc.

    collaborator INDUSTRY

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Peter Couroux, MD · Cetero Research, San Antonio

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448603 on ClinicalTrials.gov